Skip to main content
. 2020 Nov 3;51(2):273–283. doi: 10.1111/cea.13765

Table 2.

Proportion of patients with severe exacerbations

AZD9412 (N = 61) Placebo (N = 60) Ratio of proportions (95% CI) AZD9412 vs Placebo p‐value
n (%) n (%)

Severe exacerbations

Days 1 to 14

7 (11.5%) 5 (8.3%) 1.29 (0.43, 3.85) .64

Severe exacerbations

Days 1 to 30

8 (13.1%) 6 (10.0%) 1.25 (0.46, 3.41) .66

Abbreviations: CI, confidence interval; N, number; vs, versus.